what do you think of allergan. >> if he if we look at the biotech space allergan is a name that certainlynk has been more defensive there's been m and a talk and pipeline talk about you if look at the core pipeline i think it's under pressure. the valuations in the space and balance sheets in the space give you a lot ofo add one thing on allergan. if you buy the stock you are buying the risk of deal happening. the deal is not closed not closing for several months two investment things one is the deal closing and you get two thirds cash and a third stock. you do have a risk of the deal breaking then you might want to own the stock that you get in the merge he were but the first part has to happen firps. >> thoughts? >> i think to kaern karen's point, the risk is if that deal or whatever hits the skids you buy the stock now then you have a definite problem you want to -- to your point, wait until if that occurs, then you could wait and capture it on a discount, correct? >> i think if something bad happened if the deal doesn't happen just be woorp that's the risk. if you like it for the merg

economy they're wondering how much he can only contain them time when only they know positively allergan yanna now but because of a clue called clear they may push on for their own plans but remarkable and sometimes. i wouldn't push them but through. the law benevolently and austin only a little. my mind on the other lot of the bottle and on until they were then the bottle provision. was. to put the key additionally in months and i knew what i was on one of the just want to uncover. it is. only to get it in motion of the printer and of the stick all alone and then what on the get up but this tensions any thing i need put the news in the. gandhi blue bottle and on the i know what i was one of those to the not and she was. about d. . month. to month i'm going to the little. one i do know about the kids it's a muslim look put on. the bible janie was the security they were not political stuff to show the buffalo without a little got to win an open is going to say i'm going to come out on the box and look at this fish and any how much down he wants to let loose on one of them someone on. what

. >> reporter: textured implants made by allergan were taken off the market in july the fda wants manufacturers of all implants to have a warning on the package along with ingredients and a checklist for patients spelling out the risks. those proposals are now open to comment, manufacturers telling nbc news today they will review them and participate in discussion the fda is not recommending women have them removed unless they have symptoms of the lymphoma like swelling or redness but some women are choosing to take them out anyway, not wanting to wait for the worst. kristen dahlgren, nbc news, new york. >>> this evening we want to look at an issue impacting millions of american parents. the fight for paid family leave, while many companies offer it, many of them don't and in the u.s. there is no federal law requiring it and for nbc's katy tur, a new mom herself, it's an issue that hits close to home. >> reporter: this is not how she pictured her first days of motherhood. >> i would go to the hospital and see her and leave my breast milk there. i would read to her, sing to her and then go to wo

and there are real advances being made >> cgrp pill, okay allergan has, i think it is underplayed bybbvie merger is good. have you seen bristol-myers, celgene, these are wheel house stories for you. abbvie and bristol-myers, they can't grow, so they buy. >> they do abbvie buying allergan, br bristol-myers buying -- >> you're a migraine sufferer, you get 100 botox shots, not where you want them, where you need them. >> unfortunately, many times insurance will not cover that either. >> yeah, tell me about it. >> that becomes a very difficult -- >> i had a fight over my insurance. look at me, do you think i used it on my face? >> yeah, the insurers are maddening. >> yeah. >> elizabeth warren will wipe them out want to do that? >> no, i don't think she will. even if she were -- first of all, we're 100 plus days away from the iowa primary. >> which she'll win. >> which she better win. if she doesn't, then she loses a lot of momentum. secondly, by saying you think elizabeth warren will do that, you're assuming she will win the presidency third, the senate will turn democratic enough so tha

abbvi bought allergan for a $63 billion addition to stock.ve growth because of botox, and maybe the most important, the pill for acute migraines. as the spokes person for the american migrain foundation, i will predict it's going have -- going have a great bet this bill is on the verge of being improved and it will boost next year's earnings note to the fda i could use it now, please, along with millions others the netflix may change things along with ibm, but let's deal with today, i think abbvie is the way to go it and has more room to run. stick with cramer. and why is that? it aint got that vacuum in the back, whoo! sucking stuff up! what else are we gonna find? we got to go. vacuum in the back, hallelujah! get 0% financing for 60 months plus $2,250 total bonus cash on the 2019 chrysler pacifica. you should be mad they gave this guy a promotion. you should be mad at forced camaraderie. and you should be mad at tech that makes things worse. but you're not mad, because you have e*trade, who's tech makes life easier by automatically adding t

. >> buy, buy, buy >> it is true that i like the abbvie-allergan more, but it's a dynamite combo let's denise in virginia denise >> caller: hello, boo-yah, jim this is denise from virginia my husband and i are top fans. >> thank you >> caller: and recently, he's looking at jbg smith for a long-term stock portfolio. so tonight i wanted to surprise with a call to you >> if you're going to be that good of a thing, i'm going to send you back to ventoss i don't want to go far afield like you are let's go to daniel in pennsylvania daniel daniel >> yes >> come on, my brother what do you got? >> caller: yes >> you're up it's jim >> cramer. >> yeah, it's cramer >> caller: thank you for the valuable service your helping for the unsophisticated investor. >> thank you >> caller: what is your opinion about akhanna oil and gas? >> don't buy. >> sell, sell, sell, sell, sell, sell >> don't buy >> it's real bad actually, i don't want to touch it matter of fact, i often talk about, and it's about where stocks can go to if they're bad, and that's because there is no such thing as negative numbers brian i

more important the acquisition of the undermanaged allergan should be amazing.orried about botox's challengers. i'm excited about its new migraine bill to deal with pounding pain as o'a spokesperson for the american migraine foundation i can tell you the concept of acute care for migraine is a very big deal. there's nothing out there aside from standard painkillers which i regard, frankly, as a joke played on sufferers like me. this drug could be huge. novartis is under pressure because one of their subsidiaries got caught tampering with clinical trial data although the drug almost certainly would have been approved anyway. i think the problem will soon be solved 15 times next year's earnings. glaxosmithkline. ceo wamsley has moved sxhaechb earth to turn glaxo into a more r&d focused pharmaceutical company. it's clobbering the competition. eli lilly coming right back. astrazeneca some are worried their strength in their cancer franchise was climerical i think it's the real deal although the stock has run too much at this point don't want you to chase it which br

earlier this year one of the largest manufacturers of breast implant, allergan voluntarily recalled all talked to say the obvious problem from the fda proposal say implan are selected while the patient is in surgery and many patients never get to see these products' labels until the implants are already in their bodies. so that's something to consider. >> that's a problem there. >> talk about having an informational checklist for patients that they would ideally go over with their doctors so that they really sort of absorb some of the potential risks here. >> we'll be very interested to see what they make about the black box idea. >>> in a new documentary meghan markle shows how she's been struggling with the intense media scrutiny after her marriage to prince harry. we'll hear from one of meghan's >>> we have much more news. pop star lizzo is firing back after being accused of not sharing credit for writing a hit song. bruce springsteen on making music for over 50 years. >> what you try to do is the audience wants you to surprise them and make them feel at home. and the better you can

pfizer and allergan had to scrap a merger because there wasn't so much scrutiny in washington.io weiss was up for treasury secretary. elizabeth warren was one of the people very against his nomination. as a banker at lazard, he worked in a lot of inversion deals. this was very politically heated at the time. if trump decides to roll some of this back, you can bet there will be some pushback. alix: i also wonder, if it actually happens, how many companies or m&a bankers are like, cool, now we will get pretty done? sonali: probably pretty excited, let's be honest. people will be careful to dive back into bit given the political considerations, but if available, but the thing is, bank stocks plunged back then on higher pressure on inversion. they rose back up when inversions were more available,y because inversion deals were so big. alix: interesting. cinelli vasek, think you summit -- sonali ba sak, thank you so much. as bader ginsburg has spoken about her career for the latest episode of "the david rubenstein show." david asks her about the early challenges she faced. david: whe

allergan there is a pill they have migraine sufferers as the folks for the american migraine foundation they have a pill for you a kite migraine there has never been a pill. you get a mieg dpran, boom you take the -- migraine, boom, you take a pill, the pain goes away. that's what they need to replace one of the biggest drugs ever. it's huge. >> one of the components of healthcare that did see some increases in inflation this month. >> yes >> obviously >> the democrats have never really been against biotech making the big money >> it was yellen >> yellen, she didn't like playing the biotechs again, elizabeth warren, there was a good piece today about senator warren in the journal about what our life would be like with her. it would be different is the way i can describe it, but they, she's not dropping single payer. she loves single payer >> that would change a lot of our lives. >>> a lot of consumer names, kroger, jefferies goes to hold, jim talked to hormel ceo before the show and talked about plant-based foods in their global outlook take a listen everybody knows what's happening wit

going higher they love, they love, they love, they love, they love abbvie and that combination with allerganyou said was overmanaged >> right >> that was quick. i like that. i do just putting words in my mouth. >> of course >> as though i said it a thousand times i did want to mention howard hughes corporation, a company if you recall on the 27th of june, they confirmed they announced a review of strategic alternatives to what they said was maximized value, which there was hope to sell the entire company, didn't happen yesterday they announced that following that review, they will execute a transformation plan. they're going to have a new executive team, so the long time ceo david winerib is out grant herlitz will step down as well they fail to sell. they hoped, bill ackman, large shareholder, they hoped that brookfield and blackstone would be there at the time when they first announced toward the end of june this plan. that they hoped would end with a sale but it was too much for either one of them. apparently nobody can find the right fund to put the asset in has an irr that isn't as high

one of the deals he referenced on the credit side, as well, definitely on the side purchase of allergan. when you get into these, you can play it on both sides. he's playing tect side of that game >> yep >> all right brian with an amazing backdrop, thanks for joining us to wrap some of that interview dow is down 172 points >>> coming up, we're going to stay on top of the boeing story. as you've sign, the stock is down over 6% gordon bicep thuethune will joi weigh in on that, certainly from the viewpoint of someone who has run an airline >> up and next, we'll be watching this downward turn in d oc antake a look at a few of the sectors at the core of the rotation we're seeing in the markets. stay with us your brain is an amazing thing. but as you get older, it naturally begins to change, causing a lack of sharpness, or even trouble with recall. thankfully, the breakthrough in prevagen helps your brain and actually improves memory. the secret is an ingredient originally discovered... in jellyfish. in clinical trials, prevagen has been shown to improve short-term memory. prevagen. healthier